Total and free insulin-like growth factor I, insulin-like growth factor binding protein 3 and acid-labile subunit reflect clinical activity in acromegaly

Growth Hormone and IGF Research

Volumn 11, Issue 6, 2001, Pages 384-391

  Sneppen, S B ^a   Lange, M ^a   Pedersen, L M ^b   Kristensen, L O ^b   Main, K M ^a   Juul, A ^a   Skakkebak, N E ^a   Feldt Rasmussen, U ^a  

^a Rigshospitalet   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Acid labile subunit; Acromegaly; Free IGF 1; Growth hormone; IGF 1; IGFBP 3

Indexed keywords

BROMOCRIPTINE; OCTREOTIDE; PROTEIN SUBUNIT; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE MARKER; FEMALE; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; SYMPTOMATOLOGY;

EID: 0035735491     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1054/ghir.2001.0254     Document Type: Article

References (43)

1. IGFBP-3 is a poor parameter for assessment of clinical activity in acromegaly
2. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly
3. Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion
4. Criteria for cure of acromegaly: A consensus statement
5. Do "so-called" normal growth hormone concentrations (2-5 micrograms/l) indicate cure in acromegaly?
6. Serum concentrations of free and total insulin-like growth factor-I, IGF binding proteins-1 and -3 and IGFBP-3 protease activity in boys with normal or precocious puberty
7. Plasma free insulin-like growth factor 1 concentrations in growth hormone deficiency in children and adolescents
8. Serum free insulin-like growth factor-1 in growth hormone-deficient adults before and after growth hormone replacement
9. Growth hormone (GH) provocative retesting of 108 young adults with childhood-onset GH deficiency and the diagnostic value of insulin-like growth factor 1 (IGF-I) and IGF-binding protein-3
10. Free and total insulin-like growth factors and insulin-like growth factor binding proteins during 14 days of growth hormone administration in healthy adults
11. Effects of growth hormone replacement therapy on IGF-related parameters and on the pituitary-gonadal axis in GH-deficient males. A double-blind, placebo-controlled crossover study
12. Serum insulin-like growth factor-I in 1030 healthy children, adolescents and adults: Relation to age, sex, state of puperty, testicular size and body mass index
13. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: The relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation
14. Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency
15. The impact of gender and puberty on reference values for urinary growth hormone excretion: A study of 3 morning urine samples in 517 healthy children and adults
16. The ratio between serum levels of insulin like growth factor (IGF) I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients
17. Urinary growth hormone excretion in acromegaly: Diagnostic value in mild disease activity
18. Comparative study of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) level and IGF-I/IGFBP-3 ratio measurements and their relationship with an index of clinical activity in the management of acromegaly
19. A comparison of different methods for diagnosing acromegaly
20. Insulin-like growth factors (IGF)-I and -II and IGF binding protein-1, -2, and -3 in patients with acromegaly before and after adenomectomy
21. The acid-labile subunit of human ternary insulin-like growth factor binding protein complex in serum: Hepatosplanchnic release, diurnal variation, circulating concentrations in healthy subjects, and diagnostic growth hormone deficiency
22. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency
23. Acid-labile subunit of human insulin-like growth factor-binding protein complex: Measurement, molecular, and clinical evaluation
24. Measurement of the acid-labile subunit of the insulin-like growth factor binding protein complex in human serum: A comparison of four immunoassays
25. Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: Improvement of determinations in acid ethanol extracts by the use of trucated IGF-I as radioligand
26. Insulin-like growth factors (IGF-I, free IGF-I and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation
27. Wissenschaftliche Tabellen
28. The importance of insulin-like growth factor (somatomedin) measurements in the diagnosis and surveillance of acromegaly
29. Evaluation of acromegaly by radioimmunoassay of somatomedin-C
30. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: Correlation with the degree of growth hormone hypersecretion
31. Use of insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in the diagnosis of acromegaly and growth hormone deficiency in adults
32. Acromegaly: The significance of serum total and free IGF-I and IGF-binding protein-3 in diagnosis
33. Radioimmunoassay of growth hormone-dependent insulinlike growth factor binding protein in human plasma
34. A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: Its use for diagnosis of GH deficiency
35. Outpatient assessment of residual growth hormone secretion in treated acromegaly with overnight urinary growth hormone excretion, random serum growth hormone and insulin like growth factor-1
36. An audit of outcome of treatment in acromegaly
37. Value of growth hormone dynamics and somatomedin C (insulin-like growth factor I) levels in predicting the long-term benefit after transsphenoidal surgery for acromegaly
38. Investigation of the criteria for assessing the outcome of treatment in acromegaly
39. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
40. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
41. IGF-I and IGF-II in relation to colorectal cancer
42. Free insulin-like growth factor-I and breast cancer risk
43. Circulating insulin-like growth factor II and colorectal adenomas